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Early use of abiraterone 
and radium-223 in 
metastatic prostate 
cancer
Matthew Smith and colleagues1 
presented the results of the phase 3 
ERA 223 trial, in which abiraterone 
plus prednisone were combined 
with radium-223 or placebo to treat 
patients with chemotherapy-naive 
castration-resistant prostate cancer 
with bone metastases. Against all 
expectations, the study failed in 
its primary endpoint: the addition 
of radium-223 to abiraterone 
plus prednisone did not improve 
symptomatic skeletal events-free 
survival, but was associated with 
increased risk fracture, mainly in non-
metastatic bone sites. The editorial 
article by Daniel Spratt2 suggested 
that the increased bone fragility could 
be due to the synergistic inhibitory 
effect on osteoblasts from abiraterone 
and prednisone, combined with the 
osteoclastogenic effects of androgen 
deprivation, glucocorticoids, and 
radium-223. In this regard, we have 
some concerns.
Another possible reason that 
could explain the results of the 
ERA 223 study is the anabolic and anti-
resorptive effect of abiraterone on the 
bone. Indeed, our previous evidence 
showed that abiraterone treatment 
inhibited osteoclastic function, and 
promoted osteoblastic differentiation 
and bone matrix deposition, 
modulating the gene expression of 
these cells.3 Since radium-223 deposits 
mostly in active bone remodelling 
areas with high osteoblastic activity, 
the combination with abiraterone 
could induce its accumulation not 
only at metastatic sites, but also in 
healthy bone. Therefore, this abnormal 
deposition of radium-223 in healthy 
bone and the subsequent α-particle 
emission could lead to cell and tissue 
damage. This noteworthy effect of 
abiraterone in healthy bone has not 
been observed in our study with 
enzalutamide (unpublished), which 
could contribute to the lack of alert to 
bone fractures in the ongoing Peace 3 
trial (NCT02194842) treating patients 
with radium-223 combined with 
enzalutamide.
Contrary to ERA 223 data, previous 
clinical studies4,5 have shown positive 
results of the abiraterone and 
radium-223 combination, in terms of 
safety and efficacy. In these studies, 
the majority of enrolled patients 
were in the post-docetaxel setting; 
therefore, it is plausible that a previous 
cytotoxic therapy could reduce the 
anabolic response of healthy bone to 
the subsequent abiraterone treatment.
Smith and colleagues suggest 
the use of drugs for bone health 
to reduce skeletal morbidity with 
concomitant use of abiraterone and 
radium-223. However, in our opinion, 
the anabolic and antiresorptive effect 
of abiraterone warrants caution when 
these treatments are combined in the 
early settings of the disease, such as in 
the ERA 223 trial. The combination of 
new-generation drugs is developing 
within a largely unknown field 
that concerns the multifactorial 
mechanisms of bone stimulation; in 
this scenario, translational medicine 
could contribute to solve unanswered 
questions.
UD reports personal fees from Janssen, Astellas, 
Sanofi, and Bayer. MCC, DS, MI, and GP declare no 
competing interests.
*Maria Concetta Cursano, 
Daniele Santini, Michele Iuliani, 
Giovanni Paganelli, Ugo De Giorgi
m.cursano@unicampus.it
Department of Medical Oncology, 
Campus Bio-Medico University of Rome, 
00128 Rome, Italy (MCC, DS, MI); and Department 
of Medical Oncology (UD), and Nuclear Medicine 
Unit (GP), Istituto Scientifico Romagnolo per lo 
Studio e la Cura dei Tumori, Meldola, Italy
1 Smith M, Parker C, Saad F, et al. Addition of 
radium-223 to abiraterone acetate and 
prednisone or prednisolone in patients with 
castration-resistant prostate cancer and bone 
metastases (ERA 223): a randomised, 
double-blind, placebo-controlled, phase 3 trial. 
Lancet Oncol 2019; 20: 408–19.
2 Spratt DE. Combination therapies in prostate 
cancer: proceed with caution. Lancet Oncol 
2019; 20: 321–23.
